HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ratto, G. B. Articles by Vannozzi, M. O. Search for Related Content PubMed PubMed Citation Articles by Ratto, G. B. Articles by Vannozzi, M. O.

J Thorac Cardiovasc Surg 1999;117:759-765
© 1999 Mosby, Inc.

GENERAL THORACIC SURGERY

PLEURAL SPACE PERFUSION WITH CISPLATIN IN THE MULTIMODALITY TREATMENT OF MALIGNANT MESOTHELIOMA: A FEASIBILITY AND PHARMACOKINETIC STUDY

From the Istituto Anatomia Chirurgica^a and Istituto Clinica Chirurgica,^b University of Genoa; Istituto Nazionale per la Ricerca sul Cancro,^c Servizio di Farmacologia Tossicologica, Genoa, Italy.

Received for publication April 27, 1998. Revisions requested July 7, 1998. Revisions received Sept 8, 1998. Accepted for publication Dec 10, 1998. Address for reprints: Giovanni B. Ratto, MD, Istituto di Anatomia Chirurgica, Largo Rosanna Benzi 8, Università di Genova, 16132 Genova, Italy.

Introduction: Malignant pleural mesothelioma is an ideal model for testing new locoregional multimodality approaches because of its aggressive local behavior.
Methods: This study was planned to investigate the feasibility, safety, and pharmacokinetics of a multimodality therapy including an operation, pleural space perfusion (60 minutes) with cisplatin (100 mg/m²), hyperthermia (41.5°C), and postoperative radiotherapy (55 Gy to chest wall incisions). The effects of the extent of resection and perfusion temperature on cisplatin pharmacokinetics were evaluated. Ten patients with epithelial or mixed, stage I or II, malignant pleural mesothelioma underwent the following procedures: group A (3 patients), pleurectomy/decortication and normothermic pleural space antineoplastic perfusion; group B (3 patients), pleurectomy/decortication and hyperthermic perfusion; and group C (4 patients), pleuropneumonectomy and hyperthermic perfusion. Operations were selectively applied depending on tumor extent. Platinum levels were serially measured by atomic absorption in systemic blood, perfusate, lung, and endothoracic fascia.
Results: The overall procedure was completed in every case, without any death or toxicity. No lung damage was demonstrated after treatment. Major complications included 1 wound infection and 1 diaphragmatic prosthesis displacement. The mean peak platinum plasma levels were reached within 45 to 60 minutes after perfusion was started. Systemic drug concentrations were greater after pleurectomy/decortication than after pleuropneumonectomy (P = .006). The local tissue/perfusate ratio of platinum concentrations tended to be higher after hyperthermic perfusion rather than normothermic perfusion.
Conclusion: This multimodality approach is feasible, pharmacokinetically advantageous, and safe enough to undergo further clinical investigations.

This article has been cited by other articles:

				E. de Bree, S. van Ruth, C. E. Schotborgh, P. Baas, and F. A. N. Zoetmulder Limited Cardiotoxicity after Extensive Thoracic Surgery and Intraoperative Hyperthermic Intrathoracic Chemotherapy with Doxorubicin and Cisplatin Ann. Surg. Oncol., October 1, 2007; 14(10): 3019 - 3026. [Abstract] [Full Text] [PDF]

				G. L. Ceresoli, C. Gridelli, and A. Santoro Multidisciplinary Treatment of Malignant Pleural Mesothelioma Oncologist, July 1, 2007; 12(7): 850 - 863. [Abstract] [Full Text] [PDF]

				W. G. Richards, L. Zellos, R. Bueno, M. T. Jaklitsch, P. A. Janne, L. R. Chirieac, B. Y. Yeap, R. J. Dekkers, P. M. Hartigan, L. Capalbo, et al. Phase I to II Study of Pleurectomy/Decortication and Intraoperative Intracavitary Hyperthermic Cisplatin Lavage for Mesothelioma J. Clin. Oncol., April 1, 2006; 24(10): 1561 - 1567. [Abstract] [Full Text] [PDF]

				Intrapleural topical application of cisplatin with the surgical carrier Vivostat increases the local drug concentration in an immune-competent rat model with malignant pleuromesothelioma. J. Thorac. Cardiovasc. Surg., March 1, 2006; 131(3): 697 - 703.e3.

				N. Shigemura, A. Akashi, T. Nakagiri, K. Hazama, M. Ohta, and H. Matsuda Pleural perfusion thermo-chemotherapy under VATS: a new less invasive modality for advanced lung cancer with pleural spread Ann. Thorac. Surg., March 1, 2004; 77(3): 1016 - 1021. [Abstract] [Full Text] [PDF]

				S. van Ruth, P. Baas, R.L. M. Haas, E.J. Th. Rutgers, V.J. Verwaal, and F.A. N. Zoetmulder Cytoreductive Surgery Combined With Intraoperative Hyperthermic Intrathoracic Chemotherapy for Stage I Malignant Pleural Mesothelioma Ann. Surg. Oncol., March 1, 2003; 10(2): 176 - 182. [Abstract] [Full Text] [PDF]

				H. I. Pass Pleural mesothelioma in 2002: Going somewhere very slowly J. Thorac. Cardiovasc. Surg., December 1, 2002; 124(6): 1074 - 1077. [Full Text]

				C. Schroder, S. Fisher, A. C. Pieck, A. Muller, U. Jaehde, H. Kirchner, A. Haverich, and P. Macchiarini Technique and results of hyperthermic (41{degrees}C) isolated lung perfusion with high-doses of cisplatin for the treatment of surgically relapsing or unresectable lung sarcoma metastasis Eur. J. Cardiothorac. Surg., July 1, 2002; 22(1): 41 - 46. [Abstract] [Full Text] [PDF]

				Y. Refaely, D. A. Simansky, M. Paley, M. Gottfried, and A. Yellin Resection and perfusion thermochemotherapy: a new approach for the treatment of thymic malignancies with pleural spread Ann. Thorac. Surg., August 1, 2001; 72(2): 366 - 370. [Abstract] [Full Text] [PDF]

				E. G. Butchart Contemporary Management of Malignant Pleural Mesothelioma Oncologist, December 1, 1999; 4(6): 488 - 500. [Abstract] [Full Text]